The Advanced Practice Nursing Role in a High-Risk Breast Cancer Clinic

Wendy H. Vogel

ONF 2003, 30(1), 115-122. DOI: 10.1188/03.ONF.115-122

Purpose/Objectives: To describe the role of an oncology nurse practitioner in a breast cancer prevention clinic.

Data Sources: Published articles, abstracts, and book chapters and personal experience.

Data Synthesis: Validated risk assessment models and genetic screening can be used to assess an individual's risk for breast cancer. Lifestyle changes and medical interventions can reduce that risk.

Conclusions: Interventions for primary prevention of breast cancer soon may become one of the most effective means of reducing the incidence, morbidity, and mortality of breast cancer.

Implications for Nursing: Advanced practice nurses in the oncology setting are ideal healthcare providers to assess patients' risk of breast cancer, determine physical findings that can influence that risk, provide risk education, synthesize existing data, and make recommendations for surveillance, pharmacotherapy, lifestyle changes, and genetic counseling and testing. Limitations in the existing data in cancer prevention provide excellent opportunities for nursing research.

Jump to a section

    References

    American Cancer Society. (2002a). American Cancer Society guidelines on nutrition and physical activity for cancer prevention. CA: A Cancer Journal/or Clinicians, 52, 92-119.

    American Cancer Society. (2002b). Cancer facts and figures, 2002. Atlanta, GA: Author.

    American Cancer Society. (2002c). Cancer prevention and early detection facts and figures. Atlanta, GA: Author.

    American Society of Clinical Oncology. (1996). Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. Journal of Clinical Oncology, 14, 1730-1736.

    Armstrong, K., Eisen, A., & Weber, B. (2000). Assessing the risk of breast cancel. New England Journal of Medicine, 342, 564-571.

    Bernstein, L., Deapen, D., Cerhan, J.R., Schwartz, S.M., Liff, J., McGann-Maloney, E., et al. (1999). Tamoxifen therapy for breast cancer and endometrial cancer risk. Journal of the National Cancer Institute, 91, 1654-1662.

    Berry, D.A., Iversen, E.S., Jr., Gudbjartsson, D.F., Hiller, E.H., Garber, J.E., Peshkin, B.N., et al. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20, 2701-2712.

    Blackburn, K.M. (1998). Roles of advanced practice nurses in oncology. Oncology, 12, 591-596, 598, 601-603.

    Brain, K., Norman, P., Gray, J., & Mansel, R. (1999). Anxiety and adherence to breast self-examination in women with a family history of breast cancer. Psychosomatic Medicine, 61, 181-187.

    Brown, P.H., & Lippman, S.M. (2000). Chemoprevention of breast cancer. Breast Cancer Research and Treatment, 62(1), 1-17.

    Byers, T., Nestle, M., McTiernan, A., Doyle, C., Currie-Williams, A., Gansler, T., et al. (2002). American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians, 52, 92-119.

    Byrne, C., Schairer, C., Brinton, L.A., Wolfe, J., Parekh, N., Salane, M., et al. (2001). Effects of mammographic density and benign breast disease risk. Cancer Causes and Control, 12(2), 103-110.

    Carpenter, C.L., Ross, R.K., Paganin-Hill, A., & Berstein, L. (1999). Lifetime exercise activity and breast cancer risk among post-menopausal women. British Journal of Cancer, 80, 1852-1858.

    Centers for Medicare and Medicaid Services. (1997). 1997 documentation guidelines for evaluation and management services. Retrieved November 9, 2002, from http://www.cms.hhs.gov/medlearn/masterl.pdf

    Chantier, M.L., & Jahanzeb, M. (2002). Breast cancer. In R. Govindan (Ed.), The Washington manual of oncology (pp. 112-142). Philadelphia: Lippincott Williams and Wilkins.

    Glaus, E.B., Risch, N., & Thompson, W.D. (1994). Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer, 73, 643-651.

    Colditz, G.A. (1999). Hormones and breast cancer: Evidence and implications for consideration of risks and benefits of hormone replacement therapy. Journal of Women's Health, 8, 347-357.

    Couch, F.J., Cerhan, J.R., Vierkant, R.A., Grabrick, D.M., Therneau, T.M., Pankratz, V.S., et al (2001). Cigarette smoking increases risk for breast cancer in high-risk breast cancer families. Cancer Epidemiology Biomarkers and Prevention, 10, 327-332.

    Curry, L.C., & Hogstel, M.O. (2001). Risk status related to knowledge of osteoporosis in older women. Journal of Women and Aging, 13, 71-83.

    Curry, P., & Fentiman, I.S. (1999). Management of women with a family history of breast cancer. International Journal of Clinical Practice, 53, 192-196.

    Euhus, D.M. (2001). Understanding mathematical models for breast cancer risk assessment and counseling. Breast Journal, 7, 224-232.

    Fisher, B., Costantino, D., Wickerham, L., Redmond, C.K., Kavanah, M., Cronin, W.M., et al. (1998). Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute, 90, 1371-1388.

    Flach, J., & Jennings-Dozier, K.M. (2000). Bioethical considerations in cancer prevention and early detection practice and research. Oncology Nursing Forum, 27(9 Suppl.), 37-45.

    Freedman, T.G. (1998). Genetic susceptibility testing: Ethical and social quandaries. Health and Social Work, 23, 214-222.

    Gail, M.H., Brinton, L.A., Dyar, D.P., Corle, D.K., Green, S.B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81, 1879-1886.

    Gail, M.H., Constantino, J.P., Bryant, J., Croyle, R., Freedman, L., Helzlsouer, K., et al. (1999). Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. Journal of the National Cancer Institute, 91, 1829-1846.

    Geller, G., Bernhardt, B.A., Doksum, T., Helzlsouer, K.J., Wilcox, P., & Holtzman, N.A. (1998). Decision-making about breast cancer susceptibility testing: How similar are the attitudes of physicians, nurse practitioners, and at-risk women? Journal of Clinical Oncology, 16, 2868-2876.

    Grann, V.R., Jacobson, J.S., Whang, W., Hershman, D., Heitjan, D.F., Antman, K.H., et al. (2000). Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: A decision analysis. Cancer Journal From Scientific American, 6(1), 13-20.

    Greenwald, P., Sherwood, K., & McDonald, S.S. (1997). Fat, caloric intake, and obesity: Lifestyle risk factors for breast cancer. Journal of the American Dietetic Association, 97(1 Suppl.), S24-S30.

    Gulitz, E., Bustillo-Hernandez, M., & Kent, E.B. (1998). Missed cancer screening opportunities among older women: A provider survey. Cancer Practice, 6, 325-332.

    Johnson, K.C., Hu, J., & Mao, Y. (2000). Passive and active smoking and breast cancer risk in Canada, 1994-1997. Cancer Causes and Control, 11, 211-221.

    Khurana, K.K., Loosmann, A., Numann, P.J., & Khan, S.A. (2000). Prophylactic mastectomy: Pathologic findings in high-risk patients. Archives of Pathology and Laboratory Medicine, 124, 378-381.

    King, M.C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., et al. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA, 286, 2251-2256.

    Knaus, J.V. (2002). Who's liable for breast cancer prevention? Your patient can sue—and win—if preventive options aren't made clear. Postgraduate Medicine, 111(2), 63-64, 87-88, 91-92.

    Leris, C., & Mokbel, K. (2001). The prevention of breast cancer: An overview. Current Medical Research and Opinion, 16, 252-257.

    Loprinzi, C.L., Kugler, J.W., Sloan, J.A., Mailliard, J.A., La Vasseur, B.I., Barton, D.L., et al. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: A randomized controlled trial. Lancet, 356, 2059-2063.

    McTiernan, A., Kuniyuki, A., Yasui, Y., Bowen, D., Burke, W., Culver, J.B., et al. (2001). Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiology Biomarkers and Prevention, 10, 333-338.

    Morabia, A., Bernstein, M., Heritier, S., & Khatchatrian, N. (1996). Relation of breast cancer with passive and active exposure to tobacco smoke. American Journal of Epidemiology, 143, 918-928.

    Myriad Genetics, Inc. (2001). BRCA mutation guide. Salt Lake City, UT: Author.

    National Comprehensive Cancer Network. (2002). The Complete Library of Practice Guidelines in Oncology, Version 2001, With Selected 2002 Updates [CD-ROM]. Rockledge, PA: Author.

    Nogueira, S.M., & Appling, S.E. (2000). Breast cancer. Genetics, risks, and strategies. Nursing Clinics of North America, 35, 663-669.

    Olsen, O., & Gotzsche, P.C. (2001). Cochrane review on screening for breast cancer with mammography. Lancet, 358, 1340-1342.

    Pandya, K.J., Raubertas, R.F., Flynn, P.J., Hynes, H.E., Rosenbluth, R.J., Kirshner, J.J., et al. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of Internal Medicine, 132, 788-793.

    Pritchard, K.I., & Goodwin, P. (2001). Genetic predisposition and chemo-prevention: What have we learned? Retrieved January 2, 2002, from http://www.medscape.com/medscape/cno/2001/ICAT/Story.cfm?story

    Prout, M.N. (2000). Breast cancer risk reduction: What do we know and where should we go? Medscape Women's Health, 5(5). Retrieved August 19, 2001, from http://www.medscape.com/Medscape/Womenshealth/journal/2000/v05…/pnt-wh7331.prou.htm

    Rhodes, D.J., Hartmann, L.C., & Perez, E.A. (2000). Breast cancer prevention trials. Current Oncology Reports, 2, 558-565.

    Rohan, T.E., Jain, M., Howe, G.R., & Miller, A.B. (2000). Alcohol consumption and risk of breast cancer: A cohort study. Cancer Causes and Control, 11, 239-247.

    Sellers, T.A., Kushi, L.H., Cerhan, J.R., Vierkant, R.A., Gapstur, S.M., Vachon, C.M., et al. (2001). Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology, 12, 420-428.

    Smith, T.J., & Hillner, B.E. (2000). Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. Journal of Clinical Oncology, 18, 284-286.

    Smith-Warner, S.A., Spiegelman, D., Yaun, S.S., Adami, H.O., Beeson, W.L., van den Brandt, P.A., et al. (2001). Intake of fruits and vegetables and risk of breast cancer: A pooled analysis of cohort studies. JAMA, 285, 769-776.

    Thune, I. (2000). Assessments of physical activity and cancer risk. European Journal of Cancer Prevention, 9, 387-393.

    Towers, J. (1999). Medicare reimbursement for NPs. Journal of the American Academy of Nurse Practitioners, 11, 289-292.

    U.S. Preventive Services Task Force. (1997). Guide to clinical preventive services (2nd ed.). McLean, VA: International Medical Publishing.

    Willemsen, H.W., Kaas, R., Peterse, J.H., & Rutgers, E.J. (1998). Breast carcinoma in residual breast tissue after prophylactic mastectomy. European Journal of Surgical Oncology, 24, 331-332.